Skip to main content
Premium Trial:

Request an Annual Quote

Biotage Q4 Sales Increase 30 Percent; CEO Bork to Step Down

NEW YORK, Feb. 9 (GenomeWeb News) - Biotage today reported a 30-percent increase in net sales as part of its fiscal fourth-quarter earnings for 2005, and the company separately said in a statement that CEO Jeff Bork will be replaced by Torben Jörgensen, the former CEO of Affibody, effective April 27.

 

Net sales for the three months ended Oct. 1 increased 30 percent to SEK 138 million ($17.8 million) from SEK 106 million year over year.

 

R&D spending for the quarter slid to SEK 17.5 million from SEK 19.4 million in the year-ago period.

 

Fourth-quarter profit rose to SEK 2.3 million from a loss of SEK 10.6 million year over year.

 

The company had about SEK 52.8 million in cash and cash equivalents as of Dec. 31.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.